Kerckhoff Clinic Bad Nauheim, Department of Rheumatology and Immunology, University of Giessen, Germany.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S95-101. Epub 2010 Oct 28.
Low-dose methotrexate (MTX) remains the first-line treatment option among the disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. However, diverse side effects are the major reason for MTX withdrawal and change of treatment. The following article reviews the published data on general and organ-specific side effects and outlines the current recommendations addressing prevention and management of MTX-associated adverse effects.
低剂量甲氨蝶呤（MTX）仍然是类风湿关节炎患者中治疗疾病的抗风湿药物的一线治疗选择。然而，多种副作用是 MTX 停药和改变治疗的主要原因。本文综述了已发表的关于一般和器官特异性副作用的数据，并概述了目前针对 MTX 相关不良反应预防和管理的建议。
